atorvastatin has been researched along with Diabetic Glomerulosclerosis in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Christensen, BM; Grønkjaer, C; Iervolino, A; Rej, S; Thomsen, ML; Trepiccione, F | 1 |
| Maraqa, AD | 1 |
| Lei, Z; Li, T; Zuo, Y | 1 |
| Du, Y; Gao, J; Hu, R; Lu, M; Wang, Y; Wei, W; Zhang, S; Zhou, Q; Zhu, H; Zuo, L | 1 |
| Deng, T; Li, H; Li, Y; Tian, L; Zhao, P; Zhou, S | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Berg, AH; Drechsler, C; Hod, T; Kalim, S; Karumanchi, SA; Suntharalingam, P; Thadhani, RI; Wanner, C; Wenger, JB | 1 |
| Hamza, M; Shehata, M | 1 |
| Raj, DS; Ramezani, A; Velasquez, MT | 1 |
| Liao, D; Liu, YQ; Xiong, LY; Zhang, L | 1 |
| Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Matusz, P; Petrica, L; Popescu, R; Secara, A; Simulescu, A; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D; Vlad, M | 1 |
| Chaturvedi, CP; Chaudhary, DK; Ecelbarger, CM; Godbole, MM; Kumar, P; Mohan, A; Singh, RS; Tiwari, S | 1 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA | 1 |
| Kino, T; Matsuzawa, Y; Nishikawa, T; Omura, M; Saito, J; Suematsu, S | 1 |
| Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| Chen, QJ; Lu, L; Peng, WH; Shen, WF; Wang, LJ; Wang, W | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Asmus, HG; Krämer, W; Krane, V; Kühn, KW; Kütemeyer, H; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Krane, V; Wanner, C | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
2 review(s) available for atorvastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Randomized Controlled Trials as Topic | 2019 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
13 trial(s) available for atorvastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Cause of Death; Cholesterol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Renal Dialysis; Risk Factors; Serum Albumin; Survival Rate; Troponin T; Uremia | 2015 |
Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Kidney Injury; Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Double-Blind Method; Egypt; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Protective Factors; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
Topics: Aged; Albuminuria; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Male; Membrane Proteins; Middle Aged; Pilot Projects; Podocytes; Prospective Studies; Rosuvastatin Calcium; Vascular Endothelial Growth Factor A | 2017 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
12 other study(ies) available for atorvastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Atorvastatin does not ameliorate nephrogenic diabetes insipidus induced by lithium or potassium depletion in mice.
Topics: Animals; Aquaporin 2; Atorvastatin; Cell Line; Diabetes Insipidus; Diabetic Nephropathies; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypokalemia; Lithium; Male; Mice; Mice, Inbred C57BL | 2021 |
Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dinoprostone; Interleukin-1; Kidney; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tumor Necrosis Factor-alpha | 2016 |
Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Kidney Glomerulus; Kidney Tubules; Lipids; Male; MAP Kinase Signaling System; Osteopontin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats | 2014 |
Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Kidney; Lipoproteins, HDL; Lipoproteins, LDL; Male; Proteinuria; Pyrroles; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta1 | 2014 |
Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Serum Albumin | 2015 |
Renoprotective effect of atorvastatin on STZ-diabetic rats through inhibiting inflammatory factors expression in diabetic rat.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Rats; Streptozocin | 2016 |
Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ezetimibe; Histone Deacetylase Inhibitors; Histone Deacetylases; Kidney; Male; Rats; Rats, Wistar | 2016 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Topics: Aldosterone; Angiotensin II; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP11B2; Diabetic Nephropathies; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mesangial Cells; Pyrroles; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
Topics: Animals; Atorvastatin; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Streptozocin | 2011 |
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles | 2013 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |